Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis (NASDAQ:OCS) disclosed a notification under managers' transactions relating to the vesting and settlement of RSUs previously granted to director Arshad Khanani.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oculis (NASDAQ:OCS) disclosed a notification under managers' transactions relating to the vesting and settlement of RSUs previously granted to director Arshad Khanani. The notification references an RSU vest on 25 February 2026 and was published on 27 February 2026.
Details
News Market Reaction – OCS
On Mar 2, the first trading day after this news, OCS closed 2.72% below the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- Registered resale shares
- 494,259 shares
- Form F-3 warrant share resale registration
- Currently exercisable warrant
- 59,310 shares
- Portion of warrant presently exercisable
- Exercise price tranche 1
- $12.17
- Exercise price for 361,011 warrant shares
- Exercise price tranche 2
- $18.64
- Exercise price for 133,248 warrant shares
- Max cash from warrant
- $6,877,246.59
- Gross proceeds if all registered warrant shares exercised for cash
- Underwritten offering size
- 4,691,358 shares at $20.25
- Oct 31, 2025 prospectus supplement
- Registered direct shares
- 740,740 shares at $20.25
- Concurrent registered direct sale
- Current share price
- $29.99
- Pre-news trading level vs 52-week range $14–$30.68
Historical Context
-
Disclosure of earnout share vesting and removal of related restrictions for four managers.
-
Appointment of Chief Legal Officer ahead of key Phase 3 readouts and programs.
-
Showcase of late-stage ophthalmology pipeline and upcoming pivotal milestones at JPM conference.
-
FDA Breakthrough Therapy Designation for Privosegtor based on positive Phase 2 ACUITY data.
-
Administrative notification of RSU vesting and settlement for a director with no financial details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
RSUs financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.